INSM
Insmed Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -6.7% ·
share flow +8.0% ·
net new positions -7.1%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 5 | 0 | 1.38M | $155.93M | n/a | n/a |
| Q2 2026 | 158 | -6 | 147.56M | $15.74B | +6 | −11 |
| Q1 2026 | 166 | +6 | 152.11M | $24.63B | +9 | −4 |
| Q4 2025 | 159 | -1 | 156.45M | $27.23B | +1 | −1 |
| Q3 2025 | 21 | +1 | 121.03M | $17.43B | +1 | −1 |
| Q2 2025 | 18 | +1 | 70.35M | $7.08B | +2 | −1 |
| Q1 2025 | 14 | -1 | 33.99M | $2.59B | n/a | −1 |
| Q4 2024 | 15 | 0 | 31.46M | $2.17B | +1 | −1 |
| Q3 2024 | 14 | -1 | 23.46M | $1.71B | n/a | −1 |
| Q2 2024 | 15 | n/a | 25.91M | $1.74B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 12.92M | +1.7% | $985.94M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 2 | State Street Global Advisors ✦ (passive) | 5.75M | -5.9% | $438.46M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 4.29M | +4.9% | $327.26M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Adage Capital Partners ✦ | 3.45M | +109.2% | $262.97M | 0.5% | ▲ Add | 4 | SEC ↗ |
| 5 | Norges Bank ✦ (passive) | 1.74M | -5.0% | $132.96M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 6 | Duquesne Family Office ✦ | 1.37M | +130.7% | $104.44M | 3.5% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.22M | +62.5% | $93.27M | 0.0% | ▲ Add | 4 | SEC ↗ ×7 |
| 8 | D. E. Shaw & Co. ✦ | 734.88K | +44.4% | $56.06M | 0.1% | ▲ Add | 4 | SEC ↗ ×3 |
| 9 | Marshall Wace ✦ | 696.24K | -34.6% | $53.12M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 10 | Millennium Management ✦ | 679.19K | -2.8% | $51.82M | 0.1% | ▼ Trim | 4 | SEC ↗ ×2 |
| 11 | Two Sigma Investments ✦ | 406.90K | -31.5% | $31.04M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 374.81K | +15.8% | $28.59M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 307.21K | -32.5% | $23.44M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 51.24K | -20.1% | $3.91M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Renaissance Technologies | $1.75M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 664 holders, 192.22M shares, $30.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $3.10M
Director · 5.00K sh · $637,650
Officer · 239.85K sh · $31.96M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology